W 274 Pill - pink round, 10mm
Pill with imprint W 274 is Pink, Round and has been identified as Lamotrigine Extended-Release 50 mg. It is supplied by Wockhardt USA LLC.
Lamotrigine is used in the treatment of Bipolar Disorder; Lennox-Gastaut Syndrome; Epilepsy; Seizure Prevention; Seizures and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 50 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for W 274
Lamotrigine Extended-Release
- Imprint
- W 274
- Strength
- 50 mg
- Color
- Pink
- Size
- 10.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Triazine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Wockhardt USA LLC
- National Drug Code (NDC)
- 64679-0274 (Discontinued)
- Inactive Ingredients
-
diethyl phthalate,
ferric oxide red,
hypromelloses,
lactose monohydrate,
magnesium stearate,
methacrylic acid - ethyl acrylate copolymer (1:1) type a,
polyethylene glycol,
magnesium silicate,
titanium dioxide
Note: Inactive ingredients may vary.
More about lamotrigine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,766)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: triazine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Lamotrigine drug information
- Lamotrigine Chewable Dispersible Tablets
- Lamotrigine Orally Disintegrating Tablets
- Lamotrigine Extended-Release Tablets
- Lamotrigine Tablets
Other brands
Lamictal, Lamictal XR, Subvenite, Lamictal ODT, Lamictal CD
Professional resources
- Lamotrigine monograph
- Lamotrigine (FDA)
- Lamotrigine Chewable Tablet (FDA)
- Lamotrigine Extended Release Tablet (FDA)
- Lamotrigine ODT (FDA)
- Lamotrigine Tablets (FDA)
Other brands
Lamictal, Lamictal XR, Subvenite
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
